LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock
LFMDPDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 15, 2026 | $0.55 | 2026-07-02 | 2026-07-03 |
| April 15, 2026 | $0.55 | 2026-04-02 | 2026-04-03 |
| January 15, 2026 | $0.55 | 2026-01-05 | 2026-01-05 |
| October 15, 2025 | $0.55 | 2025-10-03 | 2025-10-03 |
| July 15, 2025 | $0.55 | 2025-07-03 | 2025-07-03 |
Dividends Summary
- Consistent Payer: LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock has rewarded shareholders with 19 dividend payments over the past 4 years.
- Total Returned Value: Investors who held LFMDP shares during this period received a total of $10.61 per share in dividend income.
- Latest Payout: The most recent dividend of $0.55/share was paid 3 days ago, on July 15, 2026.
- Yield & Schedule: LFMDP currently pays dividends quarterly with an annual yield of 9.51%.
- Dividend Growth: Since 2022, the dividend payout has decreased by 10.9%, from $0.62 to $0.55.
- Dividend Reliability: LFMDP has maintained or increased its dividend for 13 consecutive payments.
Company News
LifeMD announced an exclusive co-marketing collaboration with Halozyme's subsidiary Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, an FDA-approved testosterone auto-injector. The program will launch in July 2026 across 37 states, offering patients virtual clinical evaluation, lab testing, and home delivery of medicatio...
Novo Nordisk launched a subscription program for Wegovy (semaglutide) starting March 31, 2026, offering tiered pricing to reduce costs for self-pay patients. Monthly prices range from $329 to $249 for injections (up to $1,200 annual savings) and $289 to $249 for oral versions through telehealth partners including Ro, WeightWatchers, and LifeMD, w...
LifeMD announced a quarterly cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on April 15, 2026, to shareholders of record as of April 3, 2026.
Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive produ...
LifeMD, Inc. announced a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on January 15, 2026. The announcement reflects the company's financial stability as a leading virtual primary care provider.
